Search
Arbutus Biopharma Corp
ABUSAdd to Watchlist
4.555USD
+0.125+2.82%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
897.10MMarket Cap
5.49P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-17The current earnings forecast score of Arbutus Biopharma Corp is 8.67, ranking 71 out of 388 in the Biotechnology & Medical Research industry. The average price target is 5.00, with a high of 7.00 and a low of 5.00.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
5.167
Target Price
+19.60%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Arbutus Biopharma Corp
ABUS
3
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
25
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Arbutus Biopharma Corp's expected revenue for the next quarter?
Arbutus Biopharma Corp's expected revenue is 450.00K.
What is Arbutus Biopharma Corp's price target?
Analysts forecast that Arbutus Biopharma Corp's price target is USD 5.00, with the highest forecast at USD 7.00 and the lowest forecast at USD 5.00.
How have Arbutus Biopharma CorpABUS's recent earnings per share performed?
The market expectation was USD 0.88, while Arbutus Biopharma CorpABUS's earnings per share (EPS) for the previous quarter was USD -0.02. EPS for the next quarter is expected at USD -0.03.
What is the analyst rating for Arbutus Biopharma Corp?
Based on the ratings of Arbutus Biopharma Corp's stock from 3 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
